Respiratory Syncytial Virus Subgroup B Antibodies
We offer Respiratory Syncytial Virus Subgroup B Antibodies for use in common research applications: ELISA, Immunofluorescence, Western Blot. Each Respiratory Syncytial Virus Subgroup B Antibody is fully covered by our Guarantee+, to give you complete peace of mind and the support when you need it. Our Respiratory Syncytial Virus Subgroup B Antibodies can be used in a variety of model species: Virus. Use the list below to choose the Respiratory Syncytial Virus Subgroup B Antibody which is most appropriate for your research; you can click on each one to view full technical details, images, references, reviews and related products. Choose from our Respiratory Syncytial Virus Subgroup B monoclonal antibodies.
Alternate Names for Respiratory Syncytial Virus Subgroup B Antibodies
anti-Respiratory Syncytial Virus Subgroup B antibody
1 Results for "respiratory-syncytial-virus-subgroup-b" in Primary Antibodies
![Western Blot: Respiratory Syncytial Virus Subgroup B Antibody (RSV 4-14) [NBP2-50311] - The antigens used were gradient-purified RSN-2 virus in lanes 1 and 4, partial purified PVM (lane 2) and BRS virus (lane 3). First antibodies: Lane 1: RS virus convalescent human sera; Lanes 2, 3 and 4: antibody 4-14. The identity and molecular weight of the protein target of this antibody was validated by including within the immunoblot assay (as a marker) a convalescent serum sample from a RS virus infected patient. The protein specificities of the antibodies present in the convalescent serum are described in Gimenez et al. (1987).](http://images.novusbio.com/fullsize2/Respiratory Syncytial Virus Subgroup B Antibody (RSV 4-14)-Western Blot-NBP2-50311-img0001.jpg "Western Blot: Respiratory Syncytial Virus Subgroup B Antibody (RSV 4-14) [NBP2-50311] - The antigens used were gradient-purified RSN-2 virus in lanes 1 and 4, partial purified PVM (lane 2) and BRS virus (lane 3). First antibodies: Lane 1: RS virus convalescent human sera; Lanes 2, 3 and 4: antibody 4-14. The identity and molecular weight of the protein target of this antibody was validated by including within the immunoblot assay (as a marker) a convalescent serum sample from a RS virus infected patient. The protein specificities of the antibodies present in the convalescent serum are described in Gimenez et al. (1987).")